Compare $ESLA vs $INTI | Chartloom

Compare

$ESLA vs $INTI

Estrella Immunopharma Inc · Inhibitor Therapeutics Inc

ESLA

Estrella Immunopharma Inc

INTI

Inhibitor Therapeutics Inc

Compare $ESLA vs $INTI

Comparing Estrella Immunopharma Inc and Inhibitor Therapeutics Inc

ESLAEstrella Immunopharma Inc

INTIInhibitor Therapeutics Inc

ESLAEstrella Immunopharma Inc

Market cap

$18M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-70.5%

52W performance

-68.5%

FCF yield

-53.2%

INTIInhibitor Therapeutics Inc

Market cap

$17M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

108.5%

52W performance

127.9%

FCF yield

-19.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ESLA

INTI

Detailed metrics comparison

ESLA

Estrella Immunopharma Inc

INTI

Inhibitor Therapeutics Inc

Market Cap

ESLA$18M

INTI$17M

Enterprise Value

ESLA$17M

INTI$16M

Price

ESLA$0.41

INTI$0.10

P/E Ratio

ESLAN/A

INTIN/A

P/S Ratio

ESLA0.00x

INTI4.25x

EV/Sales

ESLA0.00x

INTI4.12x

EV/EBITDA

ESLA0.00x

INTI1.61x

P/B Ratio

ESLA141.63x

INTI4,922.43x

P/FCF Ratio

ESLAN/A

INTIN/A

EV/FCF

ESLA-1.86x

INTI-5.09x

PEG Ratio

ESLAN/A

INTIN/A

Forward P/E (NTM)

ESLAN/A

INTIN/A

Forward P/S (NTM)

ESLAN/A

INTIN/A

Revenue (TTM)

ESLA$0

INTI$0

Revenue Growth (YoY)

ESLAN/A

INTIN/A

Forward Rev Growth

ESLA0.0%

INTI0.0%

Gross Margin (TTM)

ESLA0.0%

INTI20.9%

Operating Margin (TTM)

ESLA0.0%

INTI0.0%

EBITDA Margin (TTM)

ESLA0.0%

INTI0.0%

Net Margin (TTM)

ESLA0.0%

INTI0.0%

FCF Margin (TTM)

ESLAN/A

INTIN/A

Net Income (TTM)

ESLA$-10M

INTI$-3M

FCF (TTM)

ESLA$-9M

INTI$-3M

EPS (TTM)

ESLA-$0.23

INTI$0.00

ROE (TTM)

ESLA-25911.0%

INTI-33792.0%

ROA (TTM)

ESLA-32876.0%

INTI-12210.0%

ROIC (TTM)

ESLA-25911.0%

INTI-33792.0%

Cash

ESLA$147K

INTI$516K

Debt

ESLA$0

INTI$0

Net Cash/Debt

ESLA$147K

INTI$516K

Current Ratio (TTM)

ESLA0.20x

INTI3.36x

Quick Ratio (TTM)

ESLA0.02x

INTI2.95x

Debt/Equity (TTM)

ESLA0.00x

INTI0.00x

Debt/Assets (TTM)

ESLA0.0%

INTI0.0%

Interest Coverage (TTM)

ESLAN/A

INTIN/A

Net Debt/EBITDA (TTM)

ESLA0.00x

INTI0.00x

Beta

ESLA0.98

INTI-0.79

52W Performance

ESLA-68.5%

INTI127.9%

YTD Performance

ESLA-70.5%

INTI108.5%

% from 52W High

ESLA-87.0%

INTI-21.0%

% from 52W Low

ESLA33.0%

INTI180.0%

Asset Turnover (TTM)

ESLA0.00x

INTI0.50x

FCF Yield (TTM)

ESLA-53.2%

INTI-19.1%

Earnings Yield (TTM)

ESLA-56.8%

INTI-15.9%

Dividend Yield (TTM)

ESLAN/A

INTIN/A

Rule of 40

ESLA0.0

INTI0.0

EV/GP/RG

ESLAN/A

INTIN/A

Ticker research

View ESLA research View INTI research

Metric	ESLA Estrella Immunopharma Inc	INTI Inhibitor Therapeutics Inc
Market & Valuation
Market Cap	$18M	$17M
Enterprise Value	$17M	$16M
Price	$0.41	$0.10
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	4.25x
EV/Sales	0.00x	4.12x
EV/EBITDA	0.00x	1.61x
P/B Ratio	141.63x	4,922.43x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.86x	-5.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	20.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-10M	$-3M
FCF (TTM)	$-9M	$-3M
EPS (TTM)	-$0.23	$0.00
ROE (TTM)	-25911.0%	-33792.0%
ROA (TTM)	-32876.0%	-12210.0%
ROIC (TTM)	-25911.0%	-33792.0%
Financial Health
Cash	$147K	$516K
Debt	$0	$0
Net Cash/Debt	$147K	$516K
Current Ratio (TTM)	0.20x	3.36x
Quick Ratio (TTM)	0.02x	2.95x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.98	-0.79
52W Performance	-68.5%	127.9%
YTD Performance	-70.5%	108.5%
% from 52W High	-87.0%	-21.0%
% from 52W Low	33.0%	180.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.50x
FCF Yield (TTM)	-53.2%	-19.1%
Earnings Yield (TTM)	-56.8%	-15.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ESLA research	View INTI research

Valuation

P/S Ratio

ESLA

0.00x

INTI

4.25x

EV/FCF

INTI

-5.09x

ESLA

-1.86x

Growth & revenue

Forward Revenue Growth

ESLA

0.0%

INTI

0.0%

Profitability & performance

Gross Margin

INTI

20.9%

ESLA

0.0%

ROE

ESLA

-25911.0%

INTI

-33792.0%

FCF Yield %

INTI

-19.1%

ESLA

-53.2%

52-Week Performance

INTI

127.9%

ESLA

-68.5%

Detailed metrics comparison

ESLA

Estrella Immunopharma Inc

INTI

Inhibitor Therapeutics Inc

Market Cap

ESLA$18M

INTI$17M

Enterprise Value

ESLA$17M

INTI$16M

Price

ESLA$0.41

INTI$0.10

P/E Ratio

ESLAN/A

INTIN/A

P/S Ratio

ESLA0.00x

INTI4.25x

EV/Sales

ESLA0.00x

INTI4.12x

EV/EBITDA

ESLA0.00x

INTI1.61x

P/B Ratio

ESLA141.63x

INTI4,922.43x

P/FCF Ratio

ESLAN/A

INTIN/A

EV/FCF

ESLA-1.86x

INTI-5.09x

PEG Ratio

ESLAN/A

INTIN/A

Forward P/E (NTM)

ESLAN/A

INTIN/A

Forward P/S (NTM)

ESLAN/A

INTIN/A

Revenue (TTM)

ESLA$0

INTI$0

Revenue Growth (YoY)

ESLAN/A

INTIN/A

Forward Rev Growth

ESLA0.0%

INTI0.0%

Gross Margin (TTM)

ESLA0.0%

INTI20.9%

Operating Margin (TTM)

ESLA0.0%

INTI0.0%

EBITDA Margin (TTM)

ESLA0.0%

INTI0.0%

Net Margin (TTM)

ESLA0.0%

INTI0.0%

FCF Margin (TTM)

ESLAN/A

INTIN/A

Net Income (TTM)

ESLA$-10M

INTI$-3M

FCF (TTM)

ESLA$-9M

INTI$-3M

EPS (TTM)

ESLA-$0.23

INTI$0.00

ROE (TTM)

ESLA-25911.0%

INTI-33792.0%

ROA (TTM)

ESLA-32876.0%

INTI-12210.0%

ROIC (TTM)

ESLA-25911.0%

INTI-33792.0%

Cash

ESLA$147K

INTI$516K

Debt

ESLA$0

INTI$0

Net Cash/Debt

ESLA$147K

INTI$516K

Current Ratio (TTM)

ESLA0.20x

INTI3.36x

Quick Ratio (TTM)

ESLA0.02x

INTI2.95x

Debt/Equity (TTM)

ESLA0.00x

INTI0.00x

Debt/Assets (TTM)

ESLA0.0%

INTI0.0%

Interest Coverage (TTM)

ESLAN/A

INTIN/A

Net Debt/EBITDA (TTM)

ESLA0.00x

INTI0.00x

Beta

ESLA0.98

INTI-0.79

52W Performance

ESLA-68.5%

INTI127.9%

YTD Performance

ESLA-70.5%

INTI108.5%

% from 52W High

ESLA-87.0%

INTI-21.0%

% from 52W Low

ESLA33.0%

INTI180.0%

Asset Turnover (TTM)

ESLA0.00x

INTI0.50x

FCF Yield (TTM)

ESLA-53.2%

INTI-19.1%

Earnings Yield (TTM)

ESLA-56.8%

INTI-15.9%

Dividend Yield (TTM)

ESLAN/A

INTIN/A

Rule of 40

ESLA0.0

INTI0.0

EV/GP/RG

ESLAN/A

INTIN/A

Ticker research

View ESLA research View INTI research

Metric	ESLA Estrella Immunopharma Inc	INTI Inhibitor Therapeutics Inc
Market & Valuation
Market Cap	$18M	$17M
Enterprise Value	$17M	$16M
Price	$0.41	$0.10
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	4.25x
EV/Sales	0.00x	4.12x
EV/EBITDA	0.00x	1.61x
P/B Ratio	141.63x	4,922.43x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.86x	-5.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	20.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-10M	$-3M
FCF (TTM)	$-9M	$-3M
EPS (TTM)	-$0.23	$0.00
ROE (TTM)	-25911.0%	-33792.0%
ROA (TTM)	-32876.0%	-12210.0%
ROIC (TTM)	-25911.0%	-33792.0%
Financial Health
Cash	$147K	$516K
Debt	$0	$0
Net Cash/Debt	$147K	$516K
Current Ratio (TTM)	0.20x	3.36x
Quick Ratio (TTM)	0.02x	2.95x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.98	-0.79
52W Performance	-68.5%	127.9%
YTD Performance	-70.5%	108.5%
% from 52W High	-87.0%	-21.0%
% from 52W Low	33.0%	180.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.50x
FCF Yield (TTM)	-53.2%	-19.1%
Earnings Yield (TTM)	-56.8%	-15.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ESLA research	View INTI research